| Autor: |
van der Pool, Anne E. M., Marsman, Hendrick A., Verheij, Joanne, ten Kate, Fibo J., Eggermont, Alexander M. M., Ijzermans, Jan N. M., Verhoef, Cornelis |
| Přispěvatelé: |
Pathology, Other departments |
| Jazyk: |
angličtina |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Journal of surgical oncology, 106(7), 892-897. Wiley-Liss Inc. |
| ISSN: |
0022-4790 |
| Popis: |
Background: Chemotherapy (CTx) before resection of colorectal liver metastases (CRLM) may cause hepatic injury and postoperative complications. To ascertain whether adding bevacizumab, a monoclonal antibody against VEGF, to oxaliplatin-based CTx has an influence on liver injury and postoperative complications. Methods: Patients with CRLM who received neoadjuvant CTx and underwent resection between 2003 and 2008 were analyzed whether or not they received bevacizumab added to oxaliplatin-based CTx. Results: The total study group existed of 104 patients: 53 patients received oxaliplatin-based CTx and 51 patients received oxaliplatin-based CTx and bevacizumab. The overall complication rate (29%) was not significantly different between the two groups. The bevacizumab group exhibited less moderate sinusoidal dilatation (8% vs. 28%, P = 0.01). No difference in complication rate was found between patients given fewer than six cycles of oxaliplatin-based CTx and those given six or more cycles, or between patients with a short ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text